CYMABAY THERAPEUTICS INC's ticker is CBAY and the CUSIP is 23257D103. A total of 120 filers reported holding CYMABAY THERAPEUTICS INC in Q4 2022. The put-call ratio across all filers is 0.59 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $372,750 | +36.2% | 25,000 | 0.0% | 0.01% | +37.5% |
| Q2 2023 | $273,750 | +25.6% | 25,000 | 0.0% | 0.01% | +14.3% |
| Q1 2023 | $218,000 | +39.1% | 25,000 | 0.0% | 0.01% | +40.0% |
| Q4 2022 | $156,750 | +78.1% | 25,000 | 0.0% | 0.01% | +25.0% |
| Q3 2022 | $88,000 | +18.9% | 25,000 | 0.0% | 0.00% | +33.3% |
| Q2 2022 | $74,000 | -5.1% | 25,000 | 0.0% | 0.00% | 0.0% |
| Q1 2022 | $78,000 | -8.2% | 25,000 | 0.0% | 0.00% | 0.0% |
| Q4 2021 | $85,000 | -53.6% | 25,000 | -50.0% | 0.00% | -66.7% |
| Q3 2021 | $183,000 | +64.9% | 50,000 | +100.0% | 0.01% | +50.0% |
| Q2 2021 | $111,000 | -2.6% | 25,000 | 0.0% | 0.01% | 0.0% |
| Q1 2021 | $114,000 | -20.8% | 25,000 | 0.0% | 0.01% | -33.3% |
| Q4 2020 | $144,000 | +61.8% | 25,000 | 0.0% | 0.01% | +50.0% |
| Q3 2020 | $89,000 | +2.3% | 25,000 | 0.0% | 0.01% | -14.3% |
| Q2 2020 | $87,000 | +135.1% | 25,000 | 0.0% | 0.01% | +75.0% |
| Q1 2020 | $37,000 | -24.5% | 25,000 | 0.0% | 0.00% | +33.3% |
| Q4 2019 | $49,000 | – | 25,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Saturn V Capital Management LP | 1,629,464 | $14,208,926 | 10.61% |
| Lynx1 Capital Management LP | 1,369,927 | $11,945,763 | 9.96% |
| Versant Venture Management, LLC | 543,753 | $4,741,526 | 9.88% |
| Foresite Capital Management IV, LLC | 1,787,094 | $15,583,460 | 8.09% |
| Octagon Capital Advisors LP | 4,570,918 | $39,858,405 | 5.74% |
| ACUTA CAPITAL PARTNERS, LLC | 878,500 | $7,660,520 | 5.64% |
| TCG Crossover Management, LLC | 3,048,257 | $26,580,801 | 5.18% |
| Affinity Asset Advisors, LLC | 1,083,118 | $9,444,789 | 3.12% |
| Altium Capital Management LP | 620,000 | $5,406,400 | 3.00% |
| Bain Capital Life Sciences Investors, LLC | 2,500,000 | $21,800 | 2.72% |